Literature DB >> 1379254

Expression of the insulin-like growth factor-II/mannose-6-phosphate receptor in multiple human tissues during fetal life and early infancy.

B Funk1, U Kessler, W Eisenmenger, A Hansmann, H J Kolb, W Kiess.   

Abstract

The insulin like growth factor-II/mannose-6-phosphate (IGF-II/M6P) receptor has been detected in many cells and tissues. In the rat, there is a dramatic developmental regulation of IGF-II/M6P receptor expression, the receptor being high in fetal and neonatal tissues and declining thereafter. We have systematically studied the expression of the human IGF-II/M6P receptor protein in tissues from 10 human fetuses and infants (age 23 weeks gestation to 24 months postnatal). We have asked 1) whether there is differential expression among different organs, and 2) whether or not the human IGF-II/M6P receptor is developmentally regulated from 23 weeks gestation to 24 months postnatal. Protein was extracted from human tissues using a buffer containing 2% sodium dodecyl sulfate and 2% Triton X-100. Aliquots of the protein extracts were analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and immunoblotting using an anti-IGF-II/M6P receptor antiserum (no. 66416) and 125I-protein A or an immunoperoxidase stain. IGF-II/M6P receptor immunoreactivity was detected in all tissues studied with the highest amount of receptor being expressed in heart, thymus, and kidney and the lowest receptor content being measured in brain and muscle. The receptor content in ovary, testis, lung, and spleen was intermediate. The apparent molecular weight of the IGF-II/M6P receptor (220,000 kilos without reduction of disulfide bonds) varied among the different tissues: in brain the receptor was of lower molecular weight than in other organs. Immunoquantitation experiments employing 125I-protein A and protein extracts from human kidney at different ages revealed a small, albeit not significant, difference of the receptor content between fetal and postnatal tissues: as in other species, larger amounts of receptor seemed to be present in fetal than in postnatal organs. In addition, no significant difference of the receptor content between human fetal liver and early postnatal liver was measured employing 125I-protein A-immunoquantitation in three fetal and five postnatal liver tissue samples. The distribution of IGF-binding protein (IGEBP) species, another abundant and major class of IGF binding principles, was also measured in human fetal and early postnatal lung, liver, kidney, muscle, and brain using Western ligand blotting with 125I-IGF-II: as with IGF-II/M6P receptor immunoreactivity there was differential expression of the different classes of IGFBPs in the various organs.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1379254     DOI: 10.1210/jcem.75.2.1379254

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  25 in total

1.  Insulin-like growth factors I and II receptors in the breast cancer survival disparity among African-American women.

Authors:  S Kalla Singh; Q W Tan; C Brito; M De León; D De León
Journal:  Growth Horm IGF Res       Date:  2010-03-27       Impact factor: 2.372

Review 2.  Heterotrimeric G proteins and the single-transmembrane domain IGF-II/M6P receptor: functional interaction and relevance to cell signaling.

Authors:  C Hawkes; A Amritraj; R G Macdonald; J H Jhamandas; S Kar
Journal:  Mol Neurobiol       Date:  2007-06       Impact factor: 5.590

Review 3.  Gene therapy for metachromatic leukodystrophy.

Authors:  Jonathan B Rosenberg; Stephen M Kaminsky; Patrick Aubourg; Ronald G Crystal; Dolan Sondhi
Journal:  J Neurosci Res       Date:  2016-11       Impact factor: 4.164

4.  Clinical and metabolic correction of pompe disease by enzyme therapy in acid maltase-deficient quail.

Authors:  T Kikuchi; H W Yang; M Pennybacker; N Ichihara; M Mizutani; J L Van Hove; Y T Chen
Journal:  J Clin Invest       Date:  1998-02-15       Impact factor: 14.808

5.  Persistence of high sustained antibodies to enzyme replacement therapy despite extensive immunomodulatory therapy in an infant with Pompe disease: need for agents to target antibody-secreting plasma cells.

Authors:  Suhrad G Banugaria; Trusha T Patel; Joanne Mackey; Stuti Das; Andrea Amalfitano; Amy S Rosenberg; Joel Charrow; Y-T Chen; Priya S Kishnani
Journal:  Mol Genet Metab       Date:  2012-01-28       Impact factor: 4.797

6.  Comparative efficacy and safety of multiple routes of direct CNS administration of adeno-associated virus gene transfer vector serotype rh.10 expressing the human arylsulfatase A cDNA to nonhuman primates.

Authors:  Jonathan B Rosenberg; Dolan Sondhi; David G Rubin; Sébastien Monette; Alvin Chen; Sara Cram; Bishnu P De; Stephen M Kaminsky; Caroline Sevin; Patrick Aubourg; Ronald G Crystal
Journal:  Hum Gene Ther Clin Dev       Date:  2014-08-21       Impact factor: 5.032

7.  Restoration of muscle functionality by genetic suppression of glycogen synthesis in a murine model of Pompe disease.

Authors:  Gaelle Douillard-Guilloux; Nina Raben; Shoichi Takikita; Arnaud Ferry; Alban Vignaud; Isabelle Guillet-Deniau; Maryline Favier; Beth L Thurberg; Peter J Roach; Catherine Caillaud; Emmanuel Richard
Journal:  Hum Mol Genet       Date:  2009-12-03       Impact factor: 6.150

8.  Glycoengineered acid alpha-glucosidase with improved efficacy at correcting the metabolic aberrations and motor function deficits in a mouse model of Pompe disease.

Authors:  Yunxiang Zhu; Ji-Lei Jiang; Nathan K Gumlaw; Jinhua Zhang; Scott D Bercury; Robin J Ziegler; Karen Lee; Mariko Kudo; William M Canfield; Timothy Edmunds; Canwen Jiang; Robert J Mattaliano; Seng H Cheng
Journal:  Mol Ther       Date:  2009-03-10       Impact factor: 11.454

9.  Biological functionalization of drug delivery carriers to bypass size restrictions of receptor-mediated endocytosis independently from receptor targeting.

Authors:  Maria Ansar; Daniel Serrano; Iason Papademetriou; Tridib Kumar Bhowmick; Silvia Muro
Journal:  ACS Nano       Date:  2013-11-20       Impact factor: 15.881

10.  The pharmacological chaperone N-butyldeoxynojirimycin enhances enzyme replacement therapy in Pompe disease fibroblasts.

Authors:  Caterina Porto; Monica Cardone; Federica Fontana; Barbara Rossi; Maria Rosaria Tuzzi; Antonietta Tarallo; Maria Vittoria Barone; Generoso Andria; Giancarlo Parenti
Journal:  Mol Ther       Date:  2009-03-17       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.